Event owner lens
Use this record to benchmark whether a comparable event makes the work after the room visible. The score is 40/100, so the next move is to benchmark the weakest pillars before repeating the format.
lead or directory source agenda analysis
Fiercejpmweek 2026
This lead or directory source in Technology / AI / Startup shows 46 visible agenda rows from fiercejpmweek.com and scores 40/100: a moderate design signal with incomplete evidence. The clearest public signals sit in Future-of-Work Fit and Problem Specificity; the main limits are Follow Through and Participation Architecture. Visible mechanisms include Participant work, Network design, and Learning transfer. The public record does not show follow-up or tracking, so the score should be read as design intent rather... A practical reading: For a reader, this is mainly a warning or source-evidence record: it reads as a lead or directory source, with the strongest visible signal in future-of-work fit and problem specificity and the biggest open question around follow through and participation architecture. The practical test is whether the published agenda connects the room to post-event continuation and evidence. This page is an original public-evidence analysis, not a copy of the source agenda or an endorsement of the event. The score places the visible agenda in the moderate design signal band. The strongest visible pillars are Future-of-Work Fit, Problem Specificity, and Learning Transfer; the thinnest visible pillars are Follow Through, Participation Architecture, and Personalization. Visible mechanisms include Participant work, Network design, and Learning transfer. The extracted agenda preview includes 84 visible rows. The most common formats are Panel, Presentation, and Unknown; the most common inferred purposes are Knowledge Transfer, Unknown, and Deliberation.
Eight-pillar fingerprint
Hover any pillar to see what it measures and, where it scored low, what the agenda is missing.
Participation Architecture?30
Participation Architecture - 30/100. Participant work, contribution, interaction, and alternatives to passive broadcast.Missing: Turn passive airtime into participant work: practice, sensemaking, decisions, critique, or artifact creation.
Follow Through?5
Follow Through - 5/100. Owners, dates, commitments, progress checks, and accountability after the room.Missing: Add named owners, dates, implementation checkpoints, and a visible post-event continuation path.
Problem Specificity?52
Problem Specificity - 52/100. A clear costly problem, objective, decision, or performance target.
Personalization?37
Personalization - 37/100. Role, path, goal, preparation, or connection tailoring for participants.Missing: Create role-based paths, prepared questions, tailored breakouts, or participant-specific next steps.
Network Design?43
Network Design - 43/100. Structured weak ties, bridge-building, mixers, and relationship persistence.
Learning Transfer?47
Learning Transfer - 47/100. Applied practice, feedback, workplace use, refreshers, and 30-90 day transfer.
Evidence Maturity?45
Evidence Maturity - 45/100. Baseline, comparison, follow-up, isolation, and attribution confidence.
Future-of-Work Fit?62
Future-of-Work Fit - 62/100. Value against time, hybrid reality, accessibility, AI, and meeting load.
Fix the gaps
Field-tested exercises matched to this agenda's weakest pillars, from the exercise library.
Follow Through (5/100)
Exercises that strengthen it: Mental Toughness Workshop • WorkshopBank · 15% Solutions • WorkshopBank · Network Patches
Participation Architecture (30/100)
Exercises that strengthen it: Make A World · Awestruck 3 Minutes · Spectrum Mapping
Personalization (37/100)
Exercises that strengthen it: Journey Mapping • WorkshopBank · Group Energiser & Perspective-Changing Exercise - Paradigm... · Photo Storytelling
Agenda Preview
The actual agenda we captured. Every block is classified by format and purpose. Open any block to see how we read it; the colored edge shows whether it is participant work, broadcast, logistics, or a showcase.
Room vs wrapper
11 percent of the 84 classified blocks put participants to work; the rest broadcast, show, or handle logistics. That mix is what drives the participation score.
Participant workBroadcastShowcaseLogistics
09:25 AMOpening RemarksOpeningOrientation+
Format · BroadcastOpeningFormat not classified from the source; treated as a broadcast block by default.
Evidence basisNo participant output visible from this rowRead from source, no work signal
all eventView session pagePresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
09:30 AMGenentech at 50: The Original Biotech Writes the Next Chapter of HealthcarePresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
09:55 AMLeveraging AI-Powered Intelligence to Create a Connected, ClinOps Control TowerPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
10:20 AMPanel: Biotech’s Capital Gambit: IPOs, Private Paths and the Road AheadPanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:00 AMSmall Molecule API in 2026: Reshoring Challenges and Potent SolutionsPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:25 AMSmall molecule pipelines continue to be robust and increasingly complex and 2026 brings new challenges especially around the need for US-based development and supply options in the current geopolitical, economic and regulatory environment. If you missed JPM...PresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:25 AMExecutive Interview with Catherine Owen Adams, CEO, Acadia PharmaceuticalsPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:50 AMPanel: Beyond the Lab: How AI is Reshaping Portfolio Strategy, Capital Allocation, and R&D Investment in BiopharmaPanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
12:35 PMLight-Controlled Biomanufacturing: The Next Paradigm Shift for Complex BiologicsPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
12:55 PMPanel: Reimagining Preclinical: Innovation Under PressurePanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
01:40 PMThe Translational Engine Powering Spatial Biology for PharmaPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
02:00 PMExecutive Interview with Richard Saynor, CEO, SandozPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
02:25 PMPanel: GLP-1s and the Next Wave in Obesity TherapiesPanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
03:15 PMSmall Company, Big Impact: A Roadmap to Commercialization and Transforming a Therapeutic CategoryPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisSession topic references decisions or metrics; event-level follow-through is not shownRead from source
03:35 PMLaunching a medicine as a lean independent biotech is hard, but it’s possible with a strategic approach rooted in a clear development and commercialization path, and executing with discipline. In this fireside chat, Unicycive Therapeutics’ CEO Shalabh Gupta...Fireside chatDiscussion+
Format · BroadcastFireside chatA conversational stage format. Engaging to watch, still a broadcast format for the audience.
Evidence basisNo participant output visible from this rowRead from source, no work signal
03:35 PMPanel: Biopharma's Response to Policy WhiplashPanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
04:20 PMClosing RemarksClosingOrientation+
Format · BroadcastClosingFormat not classified from the source; treated as a broadcast block by default.
Evidence basisNo participant output visible from this rowRead from source, no work signal
09:30 AMExecutive Interview with Naoki Okamura, President and Chief Executive Officer, AstellasPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
09:50 AMSmart Bet, Only Option, or Both?: Pharma R&D turns to AIPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
10:10 AMPanel: Pharma’s Big Bets and the Resurgence of M&APanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
10:50 AMExecutive Interview with Ludovic Helfgott, EVP of Product & Portfolio Strategy, Novo NordiskPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:10 AMFireside Chat with Robert Zirkelbach, Chief Public Affairs Officer & Head of Strategic Initiatives, PhRMAFireside chatDiscussion+
Format · BroadcastFireside chatA conversational stage format. Engaging to watch, still a broadcast format for the audience.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:30 AMHow AI is Changing the Launch Playbook for Emerging PharmaPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:50 AMPanel: Next-Gen Partnerships: Unlocking Speed, Scale, and Value in Clinical DevelopmentPanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
12:35 PMHow to Best Utilize Data to Set Your Clinical Teams up for an AI FutureWorkshopParticipant work+
Format · Participant workWorkshopParticipants work on a problem and produce something. The strongest signal of participation architecture.
Evidence basisParticipant work is implied by the formatInferred from format
12:55 PMThe (Not So) Hidden Cost of Clinical DelaysWorkshopParticipant work+
Format · Participant workWorkshopParticipants work on a problem and produce something. The strongest signal of participation architecture.
Evidence basisParticipant work is implied by the formatInferred from format
01:15 PMExecutive Interview with Christine Roth, Executive Vice President and Head of Global Product Strategy and Commercialization, BayerPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
01:35 PMIntroduction to Reshoring Pharma Production at ScalePresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
01:40 PMPanel: Reshoring Pharma Production at ScalePanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
09:30 AMKeynote: Rebuilding Women’s Health from the Ground UpKeynoteExpert framing+
Format · BroadcastKeynoteA featured talk from the stage. Builds awareness and energy, produces no participant output on its own.
Evidence basisNo participant output visible from this rowRead from source, no work signal
09:50 AMBridging the Gap: Why the Future of Commercial Pharma Lives Outside the PrescriptionPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
10:10 AMExecutive Interview with Wendy Bartie, Executive Vice President, Corporate Affairs, Bristol Myers SquibbPresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
10:30 AMPanel: AI prognosis: How healthcare AI agents will evolve in 2026PanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:15 AMFollowing the adoption of ambient AI scribes in 2024, healthcare’s focus in 2025 shifted to agentic AI - intelligent systems designed to take on time-consuming tasks. Major players including Epic, Oracle, Microsoft and Salesforce are developing...WorkshopParticipant work+
Format · Participant workWorkshopParticipants work on a problem and produce something. The strongest signal of participation architecture.
Evidence basisParticipant work is implied by the formatInferred from format
11:15 AMExecutive Interview - Jennifer Goldsack, CEO, Digital Medicine Society (DiMe)PresentationKnowledge transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisNo participant output visible from this rowRead from source, no work signal
11:40 AMPanel: Federal Update with Fierce Healthcare EditorialPanelDiscussion+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisNo participant output visible from this rowRead from source, no work signal
12:25 PMIt has been a whirlwind in Washington since the Trump administration took office in late January, and Fierce Healthcare’s reporters have kept pace with all the latest developments. In this live roundtable, they’ll discuss the state of healthcare policy on...RoundtableDiscussion+
Format · Participant workRoundtableSmall-group discussion where attendees contribute directly rather than only listening.
Evidence basisParticipant work is implied by the formatInferred from format
09:25 AMOpening RemarksOpening RemarksOrientation+
Format · BroadcastOpening RemarksFraming or welcome from the stage. Orients the room, not participatory.
Evidence basisMediumRead from source
09:30 AMVirtualUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
all eventView session pagePresentationKnowledge Transfer+
Format · BroadcastPresentationSpeakers present, the audience receives. Awareness only unless paired with practice or follow-up.
Evidence basisMediumRead from source
09:30 AMGenentech at 50: The Original Biotech Writes the Next Chapter of HealthcareUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
all eventFifty years ago, two guys walked into a bar and sketched out a concept for the world’s first biotechnology company, launching Genentech and an entire industry. Today, Genentech’s CEO Ashley Magargee is stewarding the company into its next 50 years of innovation. With this keynote, Magargee reveals where scientific breakthroughs must meet advances in technology and policy to overcome barriers to care. Join us for a visionary look at how The Original Biotech company is harnessing five decades of pioneering spirit to redefine the future of healthcare.KeynoteThought Leadership+
Format · BroadcastKeynoteA featured talk from the stage. Builds awareness and energy, produces no participant output on its own.
Evidence basisMediumRead from source
09:55 AMLeveraging AI-Powered Intelligence to Create a Connected, ClinOps Control TowerUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
10:20 AMPanel: Biotech’s Capital Gambit: IPOs, Private Paths and the Road AheadPanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
all eventThe public markets have remained largely shuttered to biotech companies throughout 2025, forcing a fundamental recalculation of growth strategies across the sector. While private funding has provided a lifeline, the question looms: are companies positioning for eventual public debuts or recalibrating toward longer-term private paths? This panel will examine the strategic calculus behind capital structure decisions and whether market conditions are aligning for a meaningful reopening of the IPO window.PanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
11:00 AMSmall Molecule API in 2026: Reshoring Challenges and Potent SolutionsUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
11:25 AMSmall molecule pipelines continue to be robust and increasingly complex and 2026 brings new challenges especially around the need for US-based development and supply options in the current geopolitical, economic and regulatory environment. If you missed JPM Live hear a summary discussion with 3 industry veterans spanning over 50 years of experiences across Merck, DuPont, Wilmington PharmaTech, Sandoz, Lupin, BioDuro and Catalent discuss latest trends and solutions.UnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
11:25 AMExecutive Interview with Catherine Owen Adams, CEO, Acadia PharmaceuticalsUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
11:50 AMPanel: Beyond the Lab: How AI is Reshaping Portfolio Strategy, Capital Allocation, and R&D Investment in BiopharmaPanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
all eventAI’s influence on biopharma extends well beyond molecule design. Increasingly, it is informing how companies prioritize pipelines, allocate capital, and structure partnerships. By combining predictive models of trial success, payer uptake, and competitive dynamics with discovery insights, AI is giving leadership teams sharper tools to decide where to invest and when to pivot. This panel will explore how AI is being applied to portfolio strategy and business development, the impact on R&D investment decisions, and how boards and investors are weighing AI-driven analysis in today’s capital-constrained market. Moderator: Stephanie Butler, Senior Conference Production Director, Fierce Life SciencesPanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
12:35 PMLight-Controlled Biomanufacturing: The Next Paradigm Shift for Complex BiologicsUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
12:55 PMPanel: Reimagining Preclinical: Innovation Under PressurePanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
all eventThe FDA’s push to phase out animal testing has collided with mounting pressure to de-risk early-stage development, creating a perfect storm of regulatory and scientific challenges. As federal R&D funding faces unprecedented cuts, companies must fundamentally reimagine how breakthrough therapies reach patients. This discussion will explore the emerging technologies and partnerships reshaping preclinical development in an era of constrained resources and evolving standards.WorkshopCo Creation+
Format · Participant workWorkshopParticipants work on a problem and produce something. The strongest signal of participation architecture.
Evidence basisMediumRead from source
01:40 PMThe Translational Engine Powering Spatial Biology for PharmaUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
02:00 PMExecutive Interview with Richard Saynor, CEO, SandozUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
02:25 PMPanel: GLP-1s and the Next Wave in Obesity TherapiesPanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
03:15 PMSmall Company, Big Impact: A Roadmap to Commercialization and Transforming a Therapeutic CategoryUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
03:35 PMLaunching a medicine as a lean independent biotech is hard, but it’s possible with a strategic approach rooted in a clear development and commercialization path, and executing with discipline. In this fireside chat, Unicycive Therapeutics’ CEO Shalabh Gupta and EVP of Corporate Strategy Doug Jesmasek will share a practical playbook for building and scaling efficiently, using chronic kidney disease (CKD) and a crowded market as a real-world case study, including:Fireside ChatDeliberation+
Format · BroadcastFireside ChatA conversational stage format. Engaging to watch, still a broadcast format for the audience.
Evidence basisMediumRead from source
03:35 PMPanel: Biopharma's Response to Policy WhiplashPanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
all eventThe convergence of FDA leadership transitions, intensified pricing pressures, and persistent tariff threats has created an unprecedented policy environment for pharmaceutical companies. How industry leaders navigate this regulatory maze while maintaining innovation pipelines and investor confidence will define competitive advantage in the coming years. This panel will examine the strategic adaptations companies have made and the political realities they must master.PanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
04:20 PMClosing RemarksClosing RemarksOrientation+
Format · BroadcastClosing RemarksClosing framing from the stage. Wraps the event, not participatory.
Evidence basisMediumRead from source
09:30 AMExecutive Interview with Naoki Okamura, President and Chief Executive Officer, AstellasUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
09:50 AMSmart Bet, Only Option, or Both?: Pharma R&D turns to AIUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
all eventJoin us as we unveil groundbreaking research on how AI is transforming biopharma R&D. Our study of 500 senior executives reveals that 82% believe AI will fundamentally reshape drug discovery and development, with generative AI driving major gains in efficiency and innovation. We’ll share key findings, explore real-world use cases, and invite perspectives from leading pharma organizations on scaling AI for impact. Don’t miss this discussion on the future of R&D and patient care.BreakWellbeing+
Format · LogisticsBreakA pacing or recovery block between sessions.
Evidence basisMediumRead from source
10:10 AMPanel: Pharma’s Big Bets and the Resurgence of M&APanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
10:50 AMExecutive Interview with Ludovic Helfgott, EVP of Product & Portfolio Strategy, Novo NordiskUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
11:10 AMFireside Chat with Robert Zirkelbach, Chief Public Affairs Officer & Head of Strategic Initiatives, PhRMAFireside ChatDeliberation+
Format · BroadcastFireside ChatA conversational stage format. Engaging to watch, still a broadcast format for the audience.
Evidence basisMediumRead from source
11:30 AMHow AI is Changing the Launch Playbook for Emerging PharmaUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
11:50 AMPanel: Next-Gen Partnerships: Unlocking Speed, Scale, and Value in Clinical DevelopmentPanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
12:35 PMHow to Best Utilize Data to Set Your Clinical Teams up for an AI FutureWorkshopCo Creation+
Format · Participant workWorkshopParticipants work on a problem and produce something. The strongest signal of participation architecture.
Evidence basisMediumRead from source
12:55 PMThe (Not So) Hidden Cost of Clinical DelaysWorkshopCo Creation+
Format · Participant workWorkshopParticipants work on a problem and produce something. The strongest signal of participation architecture.
Evidence basisMediumRead from source
01:15 PMExecutive Interview with Christine Roth, Executive Vice President and Head of Global Product Strategy and Commercialization, BayerUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
01:35 PMIntroduction to Reshoring Pharma Production at ScaleUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
01:40 PMPanel: Reshoring Pharma Production at ScalePanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
09:30 AMKeynote: Rebuilding Women’s Health from the Ground UpKeynoteThought Leadership+
Format · BroadcastKeynoteA featured talk from the stage. Builds awareness and energy, produces no participant output on its own.
Evidence basisMediumRead from source
all eventThe women’s health system didn’t fail by accident. It was built without women at the center. Saundra Pelletier will discuss why legacy approaches to product development, education, and leadership have limited progress, and how Evofem is intentionally rewriting the model. From innovative engagement with healthcare professionals and consumers to elevating women in executive leadership, this keynote address will examine what it takes to build a women’s health company that truly reflects the people it serves.KeynoteThought Leadership+
Format · BroadcastKeynoteA featured talk from the stage. Builds awareness and energy, produces no participant output on its own.
Evidence basisMediumRead from source
09:50 AMBridging the Gap: Why the Future of Commercial Pharma Lives Outside the PrescriptionUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
10:10 AMExecutive Interview with Wendy Bartie, Executive Vice President, Corporate Affairs, Bristol Myers SquibbUnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
10:30 AMPanel: AI prognosis: How healthcare AI agents will evolve in 2026PanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
11:15 AMFollowing the adoption of ambient AI scribes in 2024, healthcare’s focus in 2025 shifted to agentic AI - intelligent systems designed to take on time-consuming tasks. Major players including Epic, Oracle, Microsoft and Salesforce are developing healthcare-specific AI agents, while startups are entering the market with tools for revenue cycle management, patient communications, clinical decision support and call-center automation. This session will explore the future of AI agents in healthcare and the opportunities and challenges ahead in 2026.WorkshopCo Creation+
Format · Participant workWorkshopParticipants work on a problem and produce something. The strongest signal of participation architecture.
Evidence basisMediumRead from source
11:15 AMExecutive Interview - Jennifer Goldsack, CEO, Digital Medicine Society (DiMe)UnknownUnknown+
Format · BroadcastUnknownFormat not classified from the source; treated as a broadcast block by default.
Evidence basisMediumRead from source
11:40 AMPanel: Federal Update with Fierce Healthcare EditorialPanelDeliberation+
Format · BroadcastPanelExperts discuss while the audience watches. Surfaces perspective but rarely creates participant work.
Evidence basisMediumRead from source
12:25 PMIt has been a whirlwind in Washington since the Trump administration took office in late January, and Fierce Healthcare’s reporters have kept pace with all the latest developments. In this live roundtable, they’ll discuss the state of healthcare policy on the Hill, where the industry stands and how changes could impact your business.RoundtableDeliberation+
Format · Participant workRoundtableSmall-group discussion where attendees contribute directly rather than only listening.
Evidence basisMediumRead from source
The Full Reading
Why It Ranks This Way +
Calibrated from GES design 40/100 and verified 40/100, then capped for source appears to be a guide, directory, calendar, or ancillary page rather than a source agenda.
Reader Takeaway. For a reader, this is mainly a warning or source-evidence record: it reads as a lead or directory source, with the strongest visible signal in future-of-work fit and problem specificity and the biggest open question around follow through and participation architecture. The practical test is whether the published agenda connects the room to post-event continuation and evidence.
Strongest signals: Future-of-Work Fit, Problem Specificity, and Learning Transfer. Weakest signals: Follow Through, Participation Architecture, and Personalization.
How This Agenda Could Improve +
- Add named owners, dates, implementation checkpoints, and a visible post-event continuation path.
- Turn passive airtime into participant work: practice, sensemaking, decisions, critique, or artifact creation.
- Create role-based paths, prepared questions, tailored breakouts, or participant-specific next steps.
Fastest next move: Add named owners, dated next steps, and a visible continuation path before treating the event as outcome-ready.
Role-Specific Reading +
Sponsor lens
Look beyond exposure. Strong sponsor value would show qualified interaction, problem work, buyer learning, customer evidence, or follow-up. The practical sponsor move is to look for structured introductions, buyer-seller fit, and relationship persistence.
Designer lens
The agenda is useful as a pattern sample from fiercejpmweek.com. Redesign attention should go first to the lowest-scoring pillars; in practice, turn the thinnest agenda blocks into participant work.
Executive lens
Treat the visible agenda as an operating plan. The executive move is to require owners, dates, and evidence before treating the event as strategic. If owners, proof, and follow-through are not visible, the public record does not yet prove strategic movement.
Aggregator lens
Treat the source URL as evidence, not decoration. The data-product move is to keep it as lead evidence unless a direct agenda source is also available before ranking or syndicating the record.
What GES Means Here +
The Gathering Effectiveness Score is a strict 0-100 public-evidence reading of the agenda across eight pillars. It rewards visible participant work, follow-through, transfer, network design, and proof mechanisms more than polish, speaker fame, attendance, or satisfaction.
Visible mechanisms: Participant work, Network design, Learning transfer.
Evidence boundary: Scores reflect visible agenda/source evidence and should not be read as proof of causal event impact.
Limitations, Score Caps, and Review Flags +
Limitations
- No visible follow-up, progress monitoring, or longitudinal tracking.
- Passive stage formats dominate the visible agenda.
- No baseline measurement is visible.
Score caps
- 28: Source appears to be a guide, directory, calendar, or ancillary page rather than a source agenda.
Review flags
- Fourth-loop score cap: Source appears to be a guide, directory, calendar, or ancillary page rather than a source agenda.
- Source appears to be an ancillary commercial/registration page rather than an agenda.
- Agenda is useful as a source record but weak as evidence of gathering effectiveness.
- No source-backed follow-up, validation, baseline, tracking, or impact evidence.
- No tracking, validation, feedback, or impact measurement found in the visible source text.
- Original category was unknown; publication category is inferred.
Is this proof the event worked? +
No. This is a strict public-evidence reading of the agenda. Proof would require baseline, comparison, follow-up, attribution, and impact evidence beyond the listing.
What should a reader inspect first? +
Start with the source URL, then compare the eight pillar scores against the agenda rows. The biggest opportunities usually sit in follow-through, evidence maturity, and participant work.
Why publish weak records? +
Weak records are part of the map. They show where public agendas still describe sessions and speakers more often than outcomes, commitments, transfer, or proof.
How should I use the rows? +
Read the agenda rows as the visible design trace: formats, purposes, and evidence labels show what the public source made inspectable, not everything that happened in the room. This is a source-grounded interpretation of the public agenda record, not a copy of the source, and not an endorsement of the event.
Where To Go Next
Compare this agenda against other Technology / AI / Startup events scored on the same eight pillars.